Objective: To characterize the cognitive and neuropsychiatric symptoms of patients with behavioral variant frontotemporal dementia (bvFTD) over the natural course of the disease.
Cognitive dysfunction, although usually overshadowed by prominent behavioral disturbances, is still an important symptom of behavioral variant frontotemporal dementia (bvFTD). 1, 2 Detection of the earliest cognitive deficits helps identify patients promptly and direct them to targeted therapeutic interventions, while precise understanding of the patterns of cognitive decline is essential for demonstrating effectiveness in clinical trials. However, despite a rich literature comparing the cognitive profiles of bvFTD with Alzheimer disease (AD) and other neurodegenerative dementias, a clear characterization of the progressive neuropsychological profile of bvFTD has not yet emerged. A wide variety of tests have been studied but have yielded inconsistent reports of the cognitive domains affected, and the best clinical tests to differentiate bvFTD from related disorders. Several factors contribute to such inconsistencies, including small sample sizes, tendency to group patients of varying disease severity together, lack of uniformity in patient classification, and heterogeneity of terminology. 3 Given the imminence of novel therapeutic measures and clinical trials targeting bvFTD, 4 it is critical that the field develops a systematic and comprehensive understanding of the cognitive deficits of bvFTD and their pattern of change with disease progression. To identify characteristic clinical profiles at different stages of disease severity, we used a mixed-model approach to evaluate the neuropsychological and neuropsychiatric deficits of a large cohort of patients with bvFTD, stratified by the Clinical Dementia Rating (CDR) scale. At each level of CDR, we compared the normalized scores of patients with bvFTD to an age-matched group of patients with AD dementia. METHODS Participants. Two hundred four patients meeting the International bvFTD Consortium 5 consensus research criteria for possible, probable, or definite bvFTD, and 674 patients meeting clinical criteria 6 for possible, probable, or definite AD were evaluated at the University of California San Francisco (UCSF) Memory and Aging Center (MAC). All patients with bvFTD who had undergone cognitive testing at this center were included to represent the broadest possible sample of demographic and disease characteristics. Similarly, we began with a pool of all available patients with AD dementia, and then limited them to match the age range of patients with bvFTD. All patients underwent a complete clinical and cognitive evaluation. Diagnosis was made by consensus at a multidisciplinary meeting. We also examined 126 neurologically healthy control participants matched to the mean age of both patient groups (table 1) . All participants of the study were fluent in English as an inclusion criterion, and 86% were Caucasian.
Standard protocol approvals, registrations, and patient consents. Informed consent was obtained from all participants, and the study was approved by the UCSF institutional review boards for human research.
Neuropsychological and behavioral assessment. We used a battery of neuropsychological tests detailed in previous reports 1 (e-Methods on the Neurology ® Web site at Neurology.org) to assess major cognitive domains. Based on a detailed caregiver interview, we recorded CDR 7 and the frequency-by-severity and caregiverdistress scores of Neuropsychiatric Inventory (NPI) for all patients. 8 The neuropsychological scores were standardized (z scores) based on age-matched healthy control performance. We used a cutoff score of z , 21.5 to designate clinical impairment.
Statistical analysis. We examined the neuropsychological and NPI scores at each CDR stage (very mild, CDR 5 0.5; mild, CDR 5 1; moderate, CDR 5 2; severe, CDR 5 3). In patients who had multiple evaluations, we considered only the earliest presentation within a given CDR category. Our CDR categories, within each diagnostic group, had equal representation of patients within age range distributions.
The total number of neuropsychological observations per each patient group was 620 for AD dementia (n 5 521) and 188 for bvFTD (n 5 151). Seventy-one patients with bvFTD underwent repeated neuropsychological evaluations at CDR 5 0.5 and CDR 5 1, and 18 patients with bvFTD were evaluated between CDR 5 1 and CDR 5 2 as well as across all 3 stages of disease severity. Sixty patients with AD dementia underwent repeated neuropsychological evaluations at CDR 5 0.5 and CDR 5 1, and 34 patients with AD dementia were evaluated at both CDR 5 1 and CDR 5 2, while 9 patients with AD dementia were evaluated at all 3 stages. To avoid rejecting these valuable repeated data points, we used a longitudinal mixed model using SAS Proc Mixed. Mixed models using random coefficient matrixes are robust for analysis of data with variable numbers of observations and account for both within-and betweensubject factors to provide a more accurate estimate of error. 9, 10 Unlike analysis of variance, mixed models successfully account for the repeated measures of unbalanced designs. 11 Thus, this analytic approach might be best understood as a primarily cross-sectional analysis with observations stratified by disease severity, but which advantageously provides more precise estimates of error by allowing additional within-patient time points to be modeled. The analyses were adjusted for age and sex, and patient identity was entered into the model as a repeated factor. We excluded CDR 5 3 in the neuropsychological analysis given that most patients were not able to complete neuropsychological testing at this advanced stage.
We examined the rate of disease progression in a subset of patients who were seen more than once and calculated the difference of CDR-Sum of Boxes (CDR-SOB) between the first and the last 71, n 5 18, and n 5 18 patients with bvFTD had repeated neuropsychological evaluations between CDR 5 0.5 and 1, CDR 5 1 and 2, and across all 3 stages, respectively; n 5 60, n 5 34, and n 5 9 patients with AD dementia had repeated neuropsychological evaluations between CDR 5 0.5 and 1, CDR 5 1 and 2, and across all 3 stages, respectively. evaluation divided by time between the 2 assessments. Regression diagnostics using leverage and Cook's D measures determined 5 patients with bvFTD as outliers, and these were excluded from the regression analysis (e-Methods). We used Proc GLM and analysis of covariance procedures in SAS to generate and compare the slopes.
RESULTS General cognitive dysfunction in bvFTD.
Mini-Mental State Examination (MMSE) showed cognitive deficits even at the very early stage of bvFTD (CDR 5 0.5) (figure 1A, table 2). As dementia progressed, the MMSE scores of patients with bvFTD decreased significantly ( figure 1A) . The MMSE performance was consistently superior in patients with bvFTD than in patients with AD ( figure 1A , table e-1).
Domain-specific cognitive dysfunction in bvFTD.
Episodic memory. Episodic memory performance was not impaired at the early stage of bvFTD but became Performance on attention and working memory, executive, and facial affect naming tasks by patients with bvFTD
Performance by patients with bvFTD is plotted against the stages of disease severity (very mild, CDR 5 0.5; mild, CDR 5 1; moderate, CDR 5 2). The plots depict the least square means corrected for age and sex, and the standard errors, derived from the mixed-model analysis, based on z-score estimates calculated using an age- (table 2) . Both verbal and visual free recall of patients with AD were significantly below that of patients with bvFTD at all stages of CDR ( figure 1, B and D; table 2; table  e-1) .
Visuospatial function. At CDR 5 0.5, patients with bvFTD showed a low-average/normal performance on location discrimination but already scored in the impaired range on visuoconstruction (figure 1, E and F; table 2). With advancing dementia, location discrimination also significantly declined (figure 1E, table 2). Patients with bvFTD showed intact performance on a face discrimination task during early disease, but reached impaired levels at CDR 5 2 (figure 1G, table 2). Patients with AD dementia, in contrast, were significantly impaired at CDR 5 0.5 in both location discrimination and visuoconstruction ability, and continued to decline (figure 1, E and F; table 2). Decline in visuoconstruction ability was more dramatic in patients with AD dementia compared to patients with bvFTD ( figure 1F , table e-1).
Speech and language function. At CDR 5 0.5, patients with bvFTD showed low-average/normal performance on sentence repetition and irregular word reading, yet were already impaired on confrontation naming, verbal agility, and syntax comprehension ( figure 1H , figure e-1, table 2). At CDR 5 2, patients with bvFTD showed impairment on all language tests (table 2) . At CDR 5 0.5, both AD and bvFTD patient groups showed a similar pattern of language dysfunction (figure 1H; figure e-1, B-E; table 2). Patients with AD dementia showed a dramatic progressive decline in sentence repetition, as opposed to patients with bvFTD who did not show a significant decline ( figure 1H , table e-1).
Attention and working memory. Both auditory attention and verbal working memory fell within lowaverage/normal performance at CDR 5 0.5 of bvFTD ( figure 2, A and B; table 2 ). Auditory attention ability did not show a statistically significant decrease across CDR stages of bvFTD, although verbal working memory declined significantly (figure 2, A and B; table 2). Both patient groups showed similar attention and working memory abilities except at CDR 5 2 where patients with AD dementia showed significantly worse working memory than patients with bvFTD ( figure 2, A and B; table 2 ).
Executive function. Error insensitivity was the most profound dysfunction in the executive profile of early bvFTD ( figure 2C ) and showed the highest quantitative deviation from normal (table 2). Information processing speed was clinically impaired at CDR 5 0.5 of bvFTD, while cognitive control and speed on a set-shifting task was low-average/normal (figure 2, D and G; figure e-1F; table 2). Performance on verbal (lexical and semantic) and visual (design) fluency also showed profound deficits at CDR 5 0.5 of bvFTD, and also significantly declined with progression (figure 2, E and F; figure e-1G; table 2).
Patients with AD dementia showed impaired performance in all executive tasks other than lexical fluency at CDR 5 0.5 (figure 2, D-G; figure e-1, F and G). Patients with AD dementia outperformed those with bvFTD on lexical fluency in early disease, yet progressed relatively rapidly compared to patients with bvFTD ( figure 2F , table e-1). Semantic fluency performance by both patient groups were within similar ranges ( figure 2E ). Patients with AD dementia were also consistently better in monitoring errors than patients with bvFTD ( figure 2C , table e-1).
Emotion naming. Emotion naming remained at lowaverage/normal range at CDR 5 0.5 and CDR 5 1 of bvFTD, and became impaired at CDR 5 2 (figure 2H, table 2). Patients with AD dementia, in contrast, retained their emotion naming ability throughout (figure 2H) and performed consistently better compared to patients with bvFTD (table e-1).
Neuropsychiatric symptoms of bvFTD. Patients with bvFTD reported high levels of neuropsychiatric disturbance and associated caregiver distress from the very early stage. The NPI scores and the caregiver distress increased significantly as dementia advanced (figure 3, A and B; effect of CDR: total NPI, F 5 14.08, p , 0.0001; caregiver distress, F 5 5.82, p , 0.01). At CDR 5 0.5, apathy was the highest rated behavioral disturbance of bvFTD, followed by disinhibition, abnormal eating, and motor symptoms, all of which were significantly higher compared to AD ( figure 3C , table e-2). Despite early high scores, apathy, disinhibition, eating, and motor symptoms continued to increase significantly (figure 3C, table e-2). Sleep disturbances rated low at CDR 5 0.5 of bvFTD and showed a significant increase with progression (figure 3C, table e-2). While apathy continued to Neuropsychiatric symptoms and progression of dementia Neuropsychiatric symptom battery listed in Neuropsychiatric Inventory used to assess the frequency of behavioral symptoms and their severity at the caregiver interview. The frequency-by-severity score denotes the product of the severity of any behavioral symptom graded out of 3, and the number of episodes. (A) Total of frequency-by-severity scores across all the behavioral symptoms, plotted against the disease severity denoted by 4 different CDR stages ranging from 0.5 to 3. (B) Total of caregiver distress calculated for each of the behavioral symptoms out of 5. (C) Frequency-by-severity scores at each CDR stage, for the top 9 neuropsychiatric symptoms (sorted according to score-ranks) of bvFTD and AD patient groups. CDR stages (very mild, CDR 5 0.5; mild, CDR 5 1; moderate, CDR 5 2; severe, CDR 5 3). Error bars indicate the Continued increase, all other NPI indices reached maximum levels at CDR 5 2 in bvFTD ( figure 3C ).
Sex differences. MMSE, digit span backward, and visual free recall showed relatively higher degree of impairment in female patients with bvFTD (MMSE: men 5 23.7, women 5 21.2, p , 0.05; digit span backward: men 5 3.9, women 5 3.1, p , 0.05; visual free recall: men 5 6.7, women 5 5.0, p , 0.05). Female patients with bvFTD also showed elevated delusion scores, while apathy, sleep abnormalities, and caregiver distress were elevated in male patients (apathy: men 5 8.2, women 5 6.6, p , 0.01; sleep: men 5 3.1, women 5 1.5, p , 0.01; distress: men 5 17.5, women 5 13.8, p , 0.05; delusions: men 5 0.5, women 5 1.3, p , 0.05).
Rate of disease progression. Progression of dementia (as measured by CDR-SOB, which is a broader dimensional measure of severity and is highly correlated with the nonordinal CDR total score) was significantly faster in bvFTD than in AD ( figure 3D ). Regression analysis after excluding outliers (see e-Methods) demonstrated that the slope of disease progression was significantly steeper in bvFTD than in AD (analysis of covariance, F 5 20.5, p , 0.0001), with a projected rate of increase of 2.7 CDR-SOB points/year in bvFTD and 1.4 points/year in AD. DISCUSSION This study examined the largest single cohort of patients with bvFTD reported to date with an age-matched control group of patients with AD dementia, assessed using the same neuropsychological and neuropsychiatric measures. We demonstrate the cognitive and neuropsychiatric symptoms that appear earliest in bvFTD, and identify the neuropsychological tests that are most sensitive to progression of disease, as well as those most useful for differential diagnosis. These data may be used to improve the clinical detection of bvFTD as well as to design clinical trials in which markers of disease progression have a crucial role.
The patient with very early-stage bvFTD presents decreased error sensitivity and slower response times, with intact attention, cognitive control, memory, and facial affect naming. Poor scores on language tasks is common in early bvFTD, although performance on these tasks is susceptible to nonlanguage factors such as inattention, disorganization, slowed information processing speed, and lack of effort. Their visuoperceptual abilities are mostly spared despite subtle visuoconstruction deficits.
Error insensitivity (frequency of uncorrected errors) was a highly sensitive index of early bvFTD. Previous studies have shown that working memory and inhibitory control are mediated by relatively interdependent prefrontal cortex pathways, and although both right and left dorsolateral prefrontal cortices are involved in working memory, the right lateral prefrontal cortex may be preferentially engaged when response inhibition is a necessary component of task completion. 12, 13 Right lateral prefrontal cortex, particularly the inferior frontal gyrus, is implicated in rule violation errors following failure to suppress automatic behavior, likely in conjunction with other closely networked structures mediating top-down control, including the dorsal anterior cingulate. [14] [15] [16] [17] The tendency of patients with bvFTD to commit an unusually high number of errors implicates early involvement of these right lateral prefrontal networks.
Our results demonstrate that the testing modality in which the cognitive domain is probed is crucial in bvFTD. In early bvFTD, patients showed clear impairment of information processing speed and fluency tasks, yet maintained low-average/normal performance on attention and working memory tasks. Previous reports also found low-average/normal performance on attention and working memory 1, 18 alongside clearly impaired complex executive functions in bvFTD. 1, [18] [19] [20] [21] [22] Similarly, basic visuoperceptual processing was relatively preserved in bvFTD, although patients performed below expectation on more complex visuospatial tasks. These findings underscore the effect of executive organization (e.g., relative placement of details during visuoconstruction) or divided attention on test performance. [23] [24] [25] [26] [27] Our study found that relative preservation of performance on all aspects of episodic memory tasks is characteristic of early bvFTD. Absence of early amnesia is one of the diagnostic criteria for bvFTD, 5,28 thus to a certain degree this finding is circular; however, relative preservation of memory has previously been reported in autopsy-confirmed cases of bvFTD. 29 In mild disease, patients with bvFTD demonstrated impaired free recall but maintained the capacity for recognition, suggesting that initial memory deficits occur as a result of inattentive or disorganized learning, rather than a hippocampally mediated consolidation deficit. Significant impairments in all components of memory at moderate bvFTD reflect the progression of pathologic changes to medial temporal lobes. 1, 23, 30 High levels of neuropsychiatric disturbances were consistently found across our sample. This suggests that clinically significant elevations of neuropsychiatric symptoms are the rule, and caution should be exercised when diagnosing bvFTD while such symptoms are minimal or absent. 28, 31 We identified neuropsychological tests that show significant incremental changes in bvFTD without floor or ceiling effects as effective tools to monitor progression of disease. MMSE provided a sensitive index of disease progression throughout the entire disease course. The tests continuing to show significant progressive decline after the CDR 5 1 stage included free recall, visuospatial function, setshifting, error insensitivity, semantic fluency, design fluency, emotion naming, calculations, confrontation naming, syntax comprehension, and verbal agility. These tests provide useful markers for clinical trials focused on more advanced stages of the disease. 4 Differential diagnosis of bvFTD from AD is a crucial step in patient management. At the very mild stage of the disease, patients with bvFTD significantly outperformed patients with AD dementia on episodic memory and were faster on a set-shifting task, while scoring quantitatively worse than the latter in lexical fluency, emotion naming, and error sensitivity, with the bvFTD group at CDR 5 0.5 making more errors than the AD dementia group at CDR 5 2. This pattern is consistent with the greater involvement of frontally mediated executive and socioemotional systems in bvFTD compared to AD. Patients with AD dementia showed significantly sharper decline compared to patients with bvFTD on the MMSE, visuoconstruction, working memory, sentence repetition, confrontation naming, and lexical fluency. These findings show distinct profiles of progressive decline in AD and bvFTD reflecting unique anatomical patterns of disease burden. 2, 32, 33 Poor test performance of patients with bvFTD is not always attributable to cognitive deficits but rather to noncooperation with the testing procedures. The underlying behavioral disorder inherent to bvFTD causes many patients to demonstrate an early amotivational syndrome (sometimes called "denkfaulheit" or mental laziness) 34 that reduces their attention and engagement in neuropsychological testing and makes them less concerned about accuracy. 35 These deficits are likely direct consequences of the pathologic changes occurring early in bvFTD involving ventral salience network structures, which help patients identify personally salient stimuli, 36,37 dorsal task control network structures, which aid in maintenance of task set and focused attention, 17 as well as (in a subset of bvFTD cases) the orbitofrontal/limbic network that guides emotional evaluations. 38, 39 The profound increase of rule violation errors demonstrated by patients with bvFTD both in our study and in others 12 suggests that these noncognitive performance factors likely contribute to neuropsychological scores starting from very mild stage of the disease. 40 The main limitation of this study is the assignment of diagnosis based on the imperfect standards of clinical criteria. The UCSF MAC, however, holds an excellent record of diagnostic accuracy for bvFTD syndrome (MAC 93% vs international consensus sample 86%). 5 Even if patients meeting clinical criteria for bvFTD were included who will eventually be determined not to have a frontotemporal lobar degeneration pathology, the large size of the cohort compensates for this error. Future studies involving pathologically proven samples of bvFTD patients will provide valuable input to corroborate current findings. The epidemiologic differences between bvFTD and AD introduced a few caveats into our study. First, as AD is more prevalent toward the older end of the age range and bvFTD is more prevalent toward the younger end, the normalized scores of AD may represent a slight underestimation bias while that of bvFTD may represent an overestimation bias. Based on this, the current results are more conservative in their detection of impairments in bvFTD and less conservative in contrasting bvFTD with AD. Second, the patients with bvFTD appeared to have more regularly undergone follow-up than patients with AD dementia, which may introduce a relative bias toward the number of repeated observations in each patient group. The current analysis, however, restricted to a single observation per subject within a CDR category, which minimized such bias to a certain degree. Third, our cohort included .80% white Caucasian participants who were fluent in English. Although this approach enabled us to generate a more unified sample reducing language bias on cognitive testing, it also limited generalization to other racial groups.
In conclusion, even at the earliest stages of the disease, patients with bvFTD demonstrate a number of quantitative deficits on traditional neuropsychological testing, many of which continue to show clinically significant declines with disease progression, and form a symptom profile that is significantly divergent from that seen in age-matched patients with AD dementia. 
